New monkeypox vaccine JT118 enters first human tests
NCT ID NCT07495202
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new vaccine called JT118 to see if it is safe and triggers an immune response against monkeypox. About 180 healthy adults aged 18 to 59 will receive either the vaccine or a placebo. Researchers will monitor for side effects and measure immune responses over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JT118 recombinant monkeypox protein vaccine
- What this could lead to
- If successful, this could lead to a safe and effective vaccine to prevent monkeypox infection.
- What could go wrong
- This is an early Phase 1 trial with only 180 healthy adults, so safety and immune response are still unproven. The vaccine may not generate strong enough protection or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH VOLUNTEER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Third People's Hospital
RECRUITINGShenzhen, Guangdong, 518112, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.